Search Result

Results for "

PCSK-9

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PCSK9 (86) Amyloid-β (1) ANGPTL (1) Apoptosis (1) ATTECs (1) Autophagy (1) Caspase (2) CX3CR1 (2) Drug Derivative (1) Drug Intermediate (1) E3 Ligase Ligand-Linker Conjugates (1) Endogenous Metabolite (1) Fatty Acid Synthase (FASN) (1) GLP Receptor (1) HMG Family (2) HMG-CoA Reductase (HMGCR) (2) HSV (1) Interleukin Related (3) Keap1-Nrf2 (2) LDLR (3) Ligands for E3 Ligase (1) Ligands for Target Protein for PROTAC (1) Liposome (1) NF-κB (3) NOD-like Receptor (NLR) (4) PPAR (2) Pyroptosis (2) Reference Standards (1) Ser/Thr Protease (2) Small Interfering RNA (siRNA) (7) Toll-like Receptor (TLR) (1)
By Research Areas:	Cancer (15) Cardiovascular Disease (46) Endocrinology (1) Infection (1) Inflammation/Immunology (8) Metabolic Disease (46) Neurological Disease (1)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Cationic Lipids (1) Mouse Pre-designed siRNA Sets (1) siRNA drugs (6) Human Pre-designed siRNA Sets (1) Antisense Oligonucleotides (9) siRNAs (9)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Antibodies

Oligonucleotides

Targets Recommended: PCSK9

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-148673

Laroprovstat 1 Publications Verification AZD0780; PCSK9-IN-12	PCSK9	Cardiovascular Disease Metabolic Disease
Laroprovstat (AZD0780) is an orall active *PCSK9* inhibitor. PCSK9-IN-12 has bind affinity for PCSK9 with a K_d value of <200 nM. Laroprovstat binds to a pocket in the PCSK9 C-terminal domain and does not affect the PCSK9-LDL receptor (LDLR) interaction. Laroprovstat inhibits lysosomal trafficking of PSCK9-LDLR complexes and prevents PCSK9-induced LDLR degradation. Laroprovstat can be used for the research of hypercholesterolemia .

HY-P9930

Evolocumab 3 Publications Verification AMG 145	NF-κB Ser/Thr Protease Toll-like Receptor (TLR)	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Evolocumab (AMG 145) is a human monoclonal antibody that inhibits *PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9* protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H₂O₂-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation .

HY-132591

Inclisiran Maximum Cited Publications 7 Publications Verification ALN-PCSsc	PCSK9 Small Interfering RNA (siRNA) Pyroptosis PPAR NOD-like Receptor (NLR) Caspase Interleukin Related	Cardiovascular Disease Metabolic Disease
Inclisiran is a double-stranded small interfering RNA (siRNA) molecule. Inclisiran inhibits the transcription of *PCSK9. Inclisiran inhibits Pyroptosis, activates PPARγ, and reduces NLRP3, cleaved caspase-1, IL-1β, and IL-18*. Inclisiran has anti-inflammatory, lipid-regulating and anti-atherosclerotic activities. Inclisiran can be used in researches of hyperlipidemia and cardiovascular disease (CVD) .

HY-P99187

Bococizumab PF-04950615; RN316	PCSK9	Cardiovascular Disease Metabolic Disease
Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia .

HY-P4153

Enlicitide chloride MK-0616 chloride	PCSK9	Cardiovascular Disease
Enlicitide chloride is an orally active inhibitor for *PCSK9* that blocks the interaction between LPL receptor and PSCK9, with an IC₅₀ of 2.5 nM. Enlicitide chloride can be used in the study of cardiovascular diseases such as atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome or related cardiovascular and cardiometabolic disorders .

HY-120088A

PF-06446846 hydrochloride 5+ Cited Publications	PCSK9	Cardiovascular Disease
PF-06446846 hydrochloride is an orally active and highly selective inhibitor of translation of Proprotein convertase subtilisin/kexin type 9 (PCSK9). PF-06446846 hydrochloride inhibits PCSK9 by inducing the ribosome to stall around codon 34 .

HY-P2276

Pep2-8	PCSK9	Cancer
Pep2-8 is a *PCSK9* inhibitor with a binding K_D of 0.7 μM and an IC₅₀ of 1.4 μM .

HY-P9928

Alirocumab 1 Publications Verification REGN 727; SAR 236553	PCSK9 NOD-like Receptor (NLR) Keap1-Nrf2 HMG Family NF-κB CX3CR1	Cardiovascular Disease Cancer
Alirocumab is an anti-PCSK9 human monoclonal antibody. Alirocumab inhibits *PCSK9. Alirocumab reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB* and Fractalkine/CX3CR1. Alirocumab increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab improves atherosclerosis and inflammation ^[9] .

HY-132591A

Inclisiran sodium Maximum Cited Publications 7 Publications Verification ALN-PCSsc sodium	PCSK9 Small Interfering RNA (siRNA) Pyroptosis PPAR NOD-like Receptor (NLR) Caspase Interleukin Related	Cardiovascular Disease Metabolic Disease
Inclisiran sodium is a double-stranded small interfering RNA (siRNA) molecule. Inclisiran sodium inhibits the transcription of *PCSK9. Inclisiran sodium inhibits Pyroptosis, activates PPARγ, and reduces NLRP3, cleaved caspase-1, IL-1β, and IL-18*. Inclisiran sodium has anti-inflammatory, lipid-regulating and anti-atherosclerotic activities. Inclisiran sodium can be used in researches of hyperlipidemia and cardiovascular disease (CVD) .

HY-P9928A

*Alirocumab (anti-PCSK9)* 1 Publications Verification REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)	PCSK9 NOD-like Receptor (NLR) Keap1-Nrf2 HMG Family NF-κB CX3CR1	Cardiovascular Disease Cancer
Alirocumab (anti-PCSK9) is an anti-PCSK9 human monoclonal antibody. Alirocumab (anti-PCSK9) inhibits *PCSK9. Alirocumab (anti-PCSK9) reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB* and Fractalkine/CX3CR1. Alirocumab (anti-PCSK9) increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab (anti-PCSK9) improves atherosclerosis and inflammation ^[9] .

HY-W510159

5-O-Methylembelin	PCSK9	Cardiovascular Disease
5-O-Methylembelin is a natural isocoumarin that inhibits *PCSK9, inducible degrader of the low-density lipoprotein receptor (IDLR), and sterol regulatory element binding protein 2 (SREBP2)* mRNA expression .

HY-150223

GalNAc unconjugated/naked Inclisiran 1 Publications Verification	PCSK9 Small Interfering RNA (siRNA)	Cardiovascular Disease
GalNAc unconjugated/naked Inclisiran is a double-stranded small interfering RNA molecule that targets hepatic *PCSK9* production to reduce LDL-C levels. GalNAc unconjugated/naked Inclisiran can be used in the research of cardiovascular diseases and hypercholesterolemia .

HY-12402

SBC-115076 3 Publications Verification	PCSK9	Cardiovascular Disease
SBC-115076 is a potent proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. PCSK9 is a proprotein convertase, which plays a crucial role in LDL receptor metabolism .

HY-101354

R-IMPP PF-00932239	PCSK9	Cardiovascular Disease Cancer
R-IMPP (PF-00932239) is an anti-secretagogue of *PCSK9* (IC₅₀=4.8 μM), which targets the 80S ribosome to inhibit PCSK9 protein translation .

HY-N2127

Pinostrobin 3 Publications Verification	Amyloid-β Apoptosis Ser/Thr Protease HSV Interleukin Related	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Pinostrobin is a flavonoid with anti-cancer, antioxidant, antiviral and neuroprotective activities. Pinostrobin has oral activity. Pinostrobin is a potent *PCSK9* inhibitor that inhibits the catalytic activity of *PCSK9*. Pinostrobin can be used in the research of viral infections, cancer, leukemia, cardiovascular and cerebrovascular diseases, cirrhosis, inflammation and neurological diseases .

HY-101832

SBC-110736 1 Publications Verification	PCSK9	Cardiovascular Disease Metabolic Disease
SBC-110736 is a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor extracted from patent WO2014150395A1 .

HY-143221

AS-Inclisiran sodium	Drug Intermediate	Cardiovascular Disease
AS-Inclisiran sodium is the antisense of Inclisiran (HY-132591). Inclisiran is a double-stranded small interfering RNA (siRNA) molecule. Inclisiran inhibits the transcription of *PCSK9. Inclisiran inhibits Pyroptosis, activates PPARγ, and reduces NLRP3, cleaved caspase-1, IL-1β, and IL-18*. Inclisiran has anti-inflammatory, lipid-regulating and anti-atherosclerotic activities. Inclisiran can be used in researches of hyperlipidemia and cardiovascular disease (CVD) .

HY-152221

PCSK9-IN-10	PCSK9	Cardiovascular Disease Metabolic Disease
PCSK9-IN-10 is a potent and orally active *PCSK9* inhibitor with an IC₅₀ value of 6.4 µM. PCSK9-IN-10 increases the expression of LDLR protein and decreases the expression of PCSK9. PCSK9-IN-10 reduces atherosclerosis progression. PCSK9-IN-10 has the potential for the research of hyperlipidemia .

HY-148687A

SPC5001 sodium	PCSK9	Cardiovascular Disease
SPC5001 sodium is a locked nucleic acid (LNA)-modifed antisense oligonucleotide (ASO) complementary to human PCSK9 (proprotein convertase subtilisin/kexin type 9) mRNA. SPC5001 sodium can be used for the research of hypercholesterolemia. SPC5001 sodium sequence: 5′-TGmCTACAAAACmCmCA-3′ .

HY-130245

PCSK9 degrader 1	PCSK9	Metabolic Disease
PCSK9 degrader 1 (Compound 16) is a small molecule ligand for proprotein convertase substilisin-like/kexin type 9 (PCSK9) and shows high affinity to *PCSK9* with a K_i of 107 nM. PCSK9 degrader 1 can involve in a protein-protein interaction with the low-density lipoprotein (LDL) receptor .

HY-143219

SS-Inclisiran sodium	PCSK9	Cardiovascular Disease
SS-Inclisiran sodium is a sense strand of Inclisiran (HY-132591) .

HY-152223

PCSK9-IN-11	PCSK9	Cardiovascular Disease
PCSK9-IN-11 (compound 5r) is a potent and orally active *PCSK9* inhibitor. PCSK9-IN-11 exhibits PCSK9 transcriptional inhibitory activity in HepG2 cells, with an IC₅₀ of 5.7 μM. PCSK9-IN-11 increases LDL receptor (LDLR) protein level. PCSK9-IN-11 can be used for atherosclerosis research .

HY-162562

E28362	PCSK9	Metabolic Disease Inflammation/Immunology
E28362 is an orally active lipid-lowering agent and a selective *PCSK9* antagonist. E28362 blocks the interaction between *PCSK9* and LDLR, and induces PCSK9 degradation via the ubiquitin-proteasome pathway. E28362 significantly increases the levels of cell surface and total LDLR proteins, enhances low-density lipoprotein uptake, thereby effectively reducing plasma lipids, hepatic cholesterol and triglyceride levels. E28362 shows no obvious cytotoxicity at high concentrations, and significantly attenuates atherosclerotic lesions in animal models. E28362 is an important molecule in research of hyperlipidemia and atherosclerosis .

HY-P99822

Recaticimab SHR-1209	PCSK9	Metabolic Disease
Recaticimab (SHR-1209) is a humanized IgG1 mAb that selectively targets *PCSK9*. Recaticimab reduces low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (ApoB), triglyceride (TG), and lipoprotein(a) levels. Recaticimab can be used for hyperlipidemia research .

HY-163794

DC371739	ANGPTL PCSK9	Metabolic Disease
DC371739 is a potent and orally activity *PCSK9* inhibitor. DC371739 decreases the mRNA expression of PCSK9 and ANGPTL3. DC371739 decreases the protein expression of PCSK9 and increases the protein expression of LDLR. DC371739 has the potential for the research of hyperlipidemia .

HY-157434

PCSK9-IN-23	PCSK9	Cardiovascular Disease
PCSK9-IN-23 (compound 5C) is a potent *PCSK9* inhibitor. PCSK9-IN-23 blocks PCSK9 secretion from HepG2 cells, significantly increases LDL receptor (LDLR) expression .

HY-158827A

AZD8233 sodium	PCSK9	Metabolic Disease
AZD8233 sodium, a liver-targeting antisense oligonucleotide (ASO), inhibits subtilisin/kexin type 9 (PCSK9) protein synthesis. AZD8233 sodium increases the available LDL receptors by reducing PCSK9 levels, thereby clearing LDL from the blood and decreasing LDL-C levels.

HY-148758

PCSK9-IN-13	PCSK9	Cardiovascular Disease Metabolic Disease
PCSK9-IN-13(compound 3f) is a potent *PCSK9* inhibitor, which can antagonize low-density lipoprotein (LDL) receptor binding by binding to PCSK9, with an IC₅₀ of 537 nM .

HY-143220

SS(no Galnac)-Inclisiran sodium	PCSK9 Small Interfering RNA (siRNA) Drug Derivative	Cardiovascular Disease
SS (no Galnac)-Inclisiran sodium is the sense strand of Inclisiran (HY-132591) without GalNAc modification. Inclisiran is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of *PCSK-9*. SS (no Galnac)-Inclisiran sodium can be used in cardiovascular disease research .

HY-P11071

PCSK9 Inhibitor, EGF-A	PCSK9	Cardiovascular Disease
PCSK9 Inhibitor, EGF-A is a *PCSK9* inhibitor. PCSK9 Inhibitor, EGF-A is residues 293-334 of the EGF-A domain of the low-density lipoprotein (LDL) receptor. PCSK9 Inhibitor, EGF-A can prevent PCSK9-induced intracellular LDLR degradation. PCSK9 Inhibitor, EGF-A can be used in the study of hypercholesterolemia and premature atherosclerosis .

HY-P99552

Tafolecimab IBI-306	PCSK9	Cardiovascular Disease
Tafolecimab (IBI-306) is a human lgG2 monoclonal antibody that specifically binds *PCSK-9* and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in LDL-C levels. Tafolecimab may be used in studies of hypercholesterolaemia .

HY-RS16505

Pcsk9 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Pcsk9 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pcsk9 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Pcsk9 Mouse Pre-designed siRNA Set A Pcsk9 Mouse Pre-designed siRNA Set A

HY-P99626

Frovocimab LY 3015014	PCSK9	Metabolic Disease
Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes *PCSK9. Frovocimab inhibits PCSK9* binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9 .

HY-120088

PF-06446846 5+ Cited Publications	PCSK9	Cardiovascular Disease
PF-06446846 is an orally active proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. PF-06446846 directly and selectively inhibits translation of PCSK9 by stalling the 80S ribosome in the proximity of codon region .

HY-P99816

Ralpancizumab	PCSK9	Metabolic Disease
Ralpancizumab is a selective *PCSK9* inhibitor with potential application in hemorrhagic stroke .

HY-141714

SBC-115337	PCSK9	Cardiovascular Disease Cancer
SBC-115337, as a potent benzofuran compound, is a *PCSK9* inhibitor with an IC₅₀ value of 0.5 μM .

HY-146084

PCSK9 modulator-3	PCSK9	Metabolic Disease
PCSK9 modulator-3 (Compound 13) is a potent modulator of *PCSK9* with an EC₅₀ value of 2.46 nM. PCSK9 is a recently validated target for lowering low-density lipoprotein cholesterol (LDL-C). PCSK9 modulator-3 has the potential for the research of hyperlipidemia .

HY-149310

Dim16	PCSK9 HMG-CoA Reductase (HMGCR)	Metabolic Disease
Dim16 is a dual *PCSK9* inhibitor and HMG-CoAR inhibitor, with an IC₅₀ of 0.8 nM against human PCSK9 and an IC₅₀ of 146.8 μM against HMG-CoAR. Dim16 disrupts the *PCSK9-LDLR* protein-protein interaction, inhibits the catalytic activity of HMG-CoAR, enhances cellular uptake of extracellular LDL, and suppresses PCSK9-induced platelet aggregation. Dim16 can be used in research related to hypercholesterolemia .

HY-112598A

PF-06815345 hydrochloride	PCSK9	Cardiovascular Disease Metabolic Disease
PF-06815345 hydrochloride is an orally active and potent inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) with an IC₅₀ value of 13.4 μM. PF-06815345 hydrochloride significantly decreases the PCSK9 level in vivo in mouse .

HY-P99696

Lerodalcibep LIB003	PCSK9	Cardiovascular Disease Metabolic Disease
Lerodalcibep (LIB003) is a recombinant fusion protein of a PCSK9-binding domain (adnectin) and human serum albumin. Lerodalcibep is a Lipid-lowering agent. Lerodalcibep can be used for the research of hypercholesterolemia and cardiovascular diseases .

HY-134482

PCSK9-IN-1	PCSK9	Cardiovascular Disease
PCSK9-IN-1 is a novel and highly potent cyclic peptide *PCSK9* inhibitor with a K_i value of 1.46 nM.

HY-159595

PCSK9-IN-29	LDLR PCSK9	Metabolic Disease Inflammation/Immunology
PCSK9-IN-29 is a lipid-lowering agent. PCSK9-IN-29 can increase low-density lipoprotein receptor (LDLR) protein expression and decrease *PCSK9* protein expression in hepG2 cells. PCSK9-IN-29 can reduce the levels of serum LDL-C, TC, and liver enzyme ALT in crab eating macaques fed a high-fat diet, lower body weight and fat, and increase bone mineral content. PCSK9-IN-29 can be used for research on non-alcoholic fatty liver disease and obesity .

HY-P2276A

Pep2-8 TFA	PCSK9	Cardiovascular Disease Others
Pep2-8 is a peptide which has enhanced the antagonistic activity of proprotein convertase subtilin/ kexin 9 type (PCSK9) .

HY-17640

Nicodicosapent	Fatty Acid Synthase (FASN) Autophagy	Metabolic Disease
Nicodicosapent is a fatty acid niacin conjugate that is also an inhibitor of the sterol regulatory element binding protein (SREBP), a key regulator of cholesterol metabolism proteins such as PCSK9, HMG-CoA reductase, ATP citrate lyase, and NPC1L1.

HY-128334

PCSK9 modulator-2	PCSK9	Metabolic Disease
PCSK9 modulator-2 (Compound 1) is a potent modulator of *PCSK9* with an EC₅₀ value of 202 nM. PCSK9 is a recently validated target for lowering low-density lipoprotein cholesterol (LDL-C). PCSK9 modulator-2 has the potential for the research of hyperlipidemia .

HY-141724

PCSK9 ligand 1	PCSK9	Cancer
PCSK9 ligand 1 is a selective proprotein convertase substilisin-like/kexin type 9 (PCSK9) ligand. PCSK9 ligand 1 does not affect PCSK9 function .

HY-176043

PCSK9 autophagic degrader 2	ATTECs PCSK9	Cancer
PCSK9 autophagic degrader 2 (W6) is a *PCSK9* targeted autophagosome, with an DC₅₀ of 20.6 nM. PCSK9 autophagic degrader 2 (W6) demonstrates comparable antiatherosclerosis effect and exhibits a K_D of 2.5 μM for LC3B (Pink: PCSK9 ligand HY-176044; Blue: LC3B ligand HY-176045; Black: linker HY-141373) .

HY-147252A

Bezeparsen sodium	PCSK9	Metabolic Disease
Bezeparsen sodium is a PCSK9 synthesis inhibitor .

HY-179106

PCSK9-IN-34	PCSK9	Cardiovascular Disease
PCSK9-IN-34 is a small molecule *PCSK9* inhibitor. PCSK9-IN-34 can be used for research on cardiovascular conditions .

HY-161434

PCSK9-IN-26	PCSK9	Metabolic Disease
PCSK9-IN-26 (Compound 116) is an *PCSK9* inhibitor (IC₅₀ < 1 nM). PCSK9-IN-26 can be used for metabolic research .

Cat. No.	Product Name	Target	Research Area

HY-P4153

Enlicitide chloride MK-0616 chloride	PCSK9	Cardiovascular Disease
Enlicitide chloride is an orally active inhibitor for *PCSK9* that blocks the interaction between LPL receptor and PSCK9, with an IC₅₀ of 2.5 nM. Enlicitide chloride can be used in the study of cardiovascular diseases such as atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome or related cardiovascular and cardiometabolic disorders .

HY-P2276

Pep2-8	PCSK9	Cancer
Pep2-8 is a *PCSK9* inhibitor with a binding K_D of 0.7 μM and an IC₅₀ of 1.4 μM .

HY-P11071

PCSK9 Inhibitor, EGF-A	PCSK9	Cardiovascular Disease
PCSK9 Inhibitor, EGF-A is a *PCSK9* inhibitor. PCSK9 Inhibitor, EGF-A is residues 293-334 of the EGF-A domain of the low-density lipoprotein (LDL) receptor. PCSK9 Inhibitor, EGF-A can prevent PCSK9-induced intracellular LDLR degradation. PCSK9 Inhibitor, EGF-A can be used in the study of hypercholesterolemia and premature atherosclerosis .

HY-P2276A

Pep2-8 TFA	PCSK9	Cardiovascular Disease Others
Pep2-8 is a peptide which has enhanced the antagonistic activity of proprotein convertase subtilin/ kexin 9 type (PCSK9) .

HY-P11216

Pep2-8 analogue 18	PCSK9	Cancer
Pep2-8 analogue 18 is a high affinity *PCSK9* (K_D = 6 nM) inhibitory peptide. Pep2-8 analogue 18 restores LDL uptake in HepG2 cells (EC₅₀ = 175 nM). Pep2-8 analogue 18 has good cellular safety. Pep2-8 analogue 18 can be used for research on cardiovascular conditions .

HY-W1126955

Enlicitide (decanoate) MK-0616 (decanoate)	PCSK9	Metabolic Disease Inflammation/Immunology
Enlicitide (MK-0616) decanoate is an orally active macrocyclic peptide *PCSK9* inhibitor. Enlicitide decanoate binds to *PCSK9, blocks its interaction with low-density lipoprotein receptor (LDLR*), and enhances hepatic clearance of LDL-C. Enlicitide decanoate reduces atherogenic lipoproteins, including non-HDL cholesterol, apolipoprotein B, and lipoprotein (a). Enlicitide decanoate is applicable to research related to hypercholesterolemia, heterozygous familial hypercholesterolemia, and atherosclerotic cardiovascular disease .

Cat. No.	Product Name	Target	Research Area	Image

HY-P9930

Evolocumab 3 Publications Verification AMG 145	NF-κB Ser/Thr Protease Toll-like Receptor (TLR)	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Evolocumab (AMG 145) is a human monoclonal antibody that inhibits *PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9* protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H₂O₂-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation .

HY-P99187

Bococizumab PF-04950615; RN316	PCSK9	Cardiovascular Disease Metabolic Disease
Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia .

HY-P9928

Alirocumab 1 Publications Verification REGN 727; SAR 236553	PCSK9 NOD-like Receptor (NLR) Keap1-Nrf2 HMG Family NF-κB CX3CR1	Cardiovascular Disease Cancer
Alirocumab is an anti-PCSK9 human monoclonal antibody. Alirocumab inhibits *PCSK9. Alirocumab reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB* and Fractalkine/CX3CR1. Alirocumab increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab improves atherosclerosis and inflammation ^[9] .

HY-P9928A

*Alirocumab (anti-PCSK9)* 1 Publications Verification REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)	PCSK9 NOD-like Receptor (NLR) Keap1-Nrf2 HMG Family NF-κB CX3CR1	Cardiovascular Disease Cancer
Alirocumab (anti-PCSK9) is an anti-PCSK9 human monoclonal antibody. Alirocumab (anti-PCSK9) inhibits *PCSK9. Alirocumab (anti-PCSK9) reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB* and Fractalkine/CX3CR1. Alirocumab (anti-PCSK9) increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab (anti-PCSK9) improves atherosclerosis and inflammation ^[9] .

HY-P99822

Recaticimab SHR-1209	PCSK9	Metabolic Disease
Recaticimab (SHR-1209) is a humanized IgG1 mAb that selectively targets *PCSK9*. Recaticimab reduces low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (ApoB), triglyceride (TG), and lipoprotein(a) levels. Recaticimab can be used for hyperlipidemia research .

HY-P99552

Tafolecimab IBI-306	PCSK9	Cardiovascular Disease
Tafolecimab (IBI-306) is a human lgG2 monoclonal antibody that specifically binds *PCSK-9* and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in LDL-C levels. Tafolecimab may be used in studies of hypercholesterolaemia .

HY-P99626

Frovocimab LY 3015014	PCSK9	Metabolic Disease
Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes *PCSK9. Frovocimab inhibits PCSK9* binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9 .

HY-P99816

Ralpancizumab	PCSK9	Metabolic Disease
Ralpancizumab is a selective *PCSK9* inhibitor with potential application in hemorrhagic stroke .

HY-P99696

Lerodalcibep LIB003	PCSK9	Cardiovascular Disease Metabolic Disease
Lerodalcibep (LIB003) is a recombinant fusion protein of a PCSK9-binding domain (adnectin) and human serum albumin. Lerodalcibep is a Lipid-lowering agent. Lerodalcibep can be used for the research of hypercholesterolemia and cardiovascular diseases .

HY-P991721

Ticalicibart	PCSK9	Cardiovascular Disease
Ticalicibart is a humanized IgG4κ monoclonal antibody inhibitor targeting PCSK9. Ticalicibart has anti-hyperlipidaemic activity. Ticalicibart can be used for cardiovascular disease like hypercholesterolaemia research .

HY-P990485

*Anti-PCSK9* Antibody**	PCSK9	Inflammation/Immunology
Anti-PCSK9 Antibody is a human antibody expressed in CHO, targeting *PCSK9. Anti-PCSK9* Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-PCSK9 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P99773

Ongericimab JS002	PCSK9	Cardiovascular Disease Metabolic Disease
Ongericimab (JS002) is a humanized anti-PCSK9 monoclonal antibody. Ongericimab has lipid-lowering efficacy. Ongericimab can be used in research of hypercholesteremia and hyperlipidemia .

HY-P99871

Ebronucimab AK102	PCSK9	Others
Ebronucimab (AK102) is an IgG1-λ2 antibody targeting PCSK9 and is primarily expressed by CHO DG44 (Chinese Hamster Ovary) cells .

HY-P99251

Lodelcizumab LGT209; NVP-LGT209	PCSK9	Others
Lodelcizumab is a monoclonal antibody targeting *PCSK9*. Lodelcizumab can be used for the research of hypercholesterolemia .

HY-P991343

ALD306 ALD309	PCSK9	Endocrinology
ALD306 is a human monoclonal antibody (mAb) targeting *PCSK9*. ALD306 can be used in Hypercholesterolaemia research .

HY-P992407

MEDI-4166	PCSK9 GLP Receptor	Inflammation/Immunology
MEDI-4166 is an antibody-peptide gene fusion molecule of a *PCSK9* antibody and a GLP-1 analog. MEDI-4166 is applicable to research related to type 2 diabetes .

HY-P990658

RG-7652	Inhibitory Antibodies	Inflammation/Immunology
RG-7652 is a humanized antibody expressed in CHO cells, targeting *PCSK9*. RG-7652 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.88 kDa. The isotype control for RG-7652 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

Species:	Human (9) Rhesus Macaque (1) Rat (1) Mouse (3) Cynomolgus (1)
Tag:	His (15) Avi (5) HA (1) Fc (1)
Source:	HEK293 (17)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P78574

	PCSK9 Protein, Cynomolgus (HEK293, His) PCSK9; FH3; HCHOLA3; LDLCQ1; NARC1; PC9	Cynomolgus	HEK293
	PCSK9 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived PCSK9, expressed by HEK293 , with C-His labeled tag. ,

HY-P78690

	PCSK9 Protein, Hamster (HEK293, His) PCSK9; FH3; HCHOLA3; LDLCQ1; NARC1; PC9	Others	HEK293
	The PCSK9 protein is an important regulator of plasma cholesterol homeostasis, affecting LDL receptor family members such as LDLR and VLDLR. It promotes their intracellular degradation and enhances hepatic LDLR degradation through non-proteolytic mechanisms. PCSK9 Protein, Hamster (HEK293, His) is the recombinant PCSK9 protein, expressed by HEK293 , with C-His labeled tag. The total length of PCSK9 Protein, Hamster (HEK293, His) is 662 a.a., with molecular weight of ~18 kDa.

HY-P78825

	PCSK9 Protein, Mouse (Biotinylated, HEK293, His-Avi) PCSK9; FH3; HCHOLA3; LDLCQ1; NARC1; PC9	Mouse	HEK293
	The PCSK9 protein is an important regulator of plasma cholesterol homeostasis, affecting LDL receptor family members such as LDLR and VLDLR. It promotes their intracellular degradation and enhances hepatic LDLR degradation through non-proteolytic mechanisms. PCSK9 Protein, Mouse (Biotinylated, HEK293, His-Avi) is the recombinant mouse-derived PCSK9 protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of PCSK9 Protein, Mouse (Biotinylated, HEK293, His-Avi) is 660 a.a., with molecular weight of ~17 kDa.

HY-P78663

	PCSK9 Protein, Human (D374Y, HEK293, His) PCSK9; FH3; HCHOLA3; LDLCQ1; NARC1; PC9	Human	HEK293
	The PCSK9 protein is an important regulator of plasma cholesterol homeostasis, affecting LDL receptor family members such as LDLR and VLDLR. It promotes their intracellular degradation and enhances hepatic LDLR degradation through non-proteolytic mechanisms. PCSK9 Protein, Human (D374Y, HEK293, His) is the recombinant human-derived PCSK9 protein, expressed by HEK293 , with C-10*His labeled tag and D374Y mutation.

HY-P78824

	PCSK9 Protein, Human (Biotinylated, HEK293, D374Y, His-Avi) PCSK9; FH3; HCHOLA3; LDLCQ1; NARC1; PC9	Human	HEK293
	The PCSK9 protein is an important regulator of plasma cholesterol homeostasis, affecting LDL receptor family members such as LDLR and VLDLR. It promotes their intracellular degradation and enhances hepatic LDLR degradation through non-proteolytic mechanisms. PCSK9 Protein, Human (Biotinylated, HEK293, D374Y, His-Avi) is the recombinant human-derived PCSK9 protein, expressed by HEK293 , with C-Avi, C-His labeled tag and D374Y, , , , mutation.

HY-P73728

	PCSK9 Protein, Human (HEK293, mFc) 1 Publications Verification Proprotein convertase subtilisin/kexin type 9; NARC-1; PC9; PCSK9	Human	HEK293
	The PCSK9 protein is an important regulator of plasma cholesterol homeostasis, affecting LDL receptor family members such as LDLR and VLDLR. It promotes their intracellular degradation and enhances hepatic LDLR degradation through non-proteolytic mechanisms. PCSK9 Protein, Human (HEK293, mFc) is the recombinant human-derived PCSK9 protein, expressed by HEK293 , with C-mFc labeled tag.

HY-P73340

	PCSK9 Protein, Rat (HEK293, His) 1 Publications Verification Proprotein convertase subtilisin/kexin type 9; NARC-1; PC9; PCSK9	Rat	HEK293
	The PCSK9 protein regulates cholesterol levels by interacting with LDLR, VLDLR, LRP1/APOER, and LRP8/APOER2. It promotes their degradation and inhibits their recycling, leading to enhanced LDLR degradation. PCSK9 also affects APOB degradation, BACE1 intermediates, ENaC surface expression, and neuronal apoptosis via LRP8/APOER2. PCSK9 Protein, Rat (HEK293, His) is the recombinant rat-derived PCSK9 protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P70966

	PCSK9 Protein, Macaca nemestrina (HEK293, His) Proprotein Convertase Subtilisin/Kexin Type 9; Proprotein Convertase 9; PC9; Subtilisin/Kexin-Like Protease PC9; PCSK9	Others	HEK293
	The PCSK9 protein controls plasma cholesterol levels by interacting with LDLR, VLDLR, LRP1/APOER, and LRP8/APOER2 to promote their degradation. It prevents LDLR recycling and directs it to lysosomes for degradation. PCSK9 induces LDLR ubiquitination, inhibits APOB degradation, disposes of BACE1 intermediates, reduces ENaC surface expression, and regulates neuronal apoptosis through LRP8/APOER2. PCSK9 Protein, Macaca nemestrina (HEK293, His) is the recombinant cynomolgus-derived PCSK9 protein, expressed by HEK293, with C-6*His labeled tag.

HY-P75958

	PCSK9 Protein, Rhesus Macaque (HEK293, His) Proprotein convertase subtilisin/kexin type 9; NARC-1; PC9; PCSK9	Rhesus Macaque	HEK293
	PCSK9 protein regulates cholesterol levels by degrading LDLR, VLDLR, LRP1/APOER and LRP8/APOER2 receptors. It promotes LDLR degradation through non-proteolytic mechanisms, disrupts LDLR recycling, induces LDLR ubiquitination, and inhibits APOB degradation. PCSK9 Protein, Rhesus Macaque (HEK293, His) is the recombinant Rhesus Macaque-derived PCSK9 protein, expressed by HEK293 , with C-His labeled tag.

HY-P71189

	PCSK9 Protein, Mouse (HEK293, His, solution) Proprotein Convertase Subtilisin/Kexin Type 9; Neural Apoptosis-Regulated Convertase 1; NARC-1; Proprotein Convertase 9; PC9; Subtilisin/Kexin-Like Protease PC9; PCSK9; Narc1	Mouse	HEK293
	The PCSK9 protein regulates cholesterol levels by degrading LDLR, VLDLR, LRP1/APOER, and LRP8/APOER2 receptors. It promotes LDLR degradation, inhibits recycling, induces ubiquitination, and affects APOB degradation. Additionally, PCSK9 influences BACE1 intermediates, ENaC surface expression, and neuronal apoptosis by modulating LRP8/APOER2 levels and anti-apoptotic signaling pathways. PCSK9 Protein, Mouse (HEK293, His, solution) is the recombinant mouse-derived PCSK9 protein, expressed by HEK293, with C-6*His labeled tag.

HY-P704837

	PCSK9 Protein, Human (419a.a, HEK293, His) Proprotein Convertase Subtilisin/Kexin Type 9; Neural Apoptosis-Regulated Convertase 1; NARC-1; Proprotein Convertase 9; PC9; Subtilisin/Kexin-Like Protease PC9; PCSK9; NARC1	Human	HEK293
	The PCSK9 protein is an important regulator of plasma cholesterol homeostasis, affecting LDL receptor family members such as LDLR and VLDLR. It promotes their intracellular degradation and enhances hepatic LDLR degradation through non-proteolytic mechanisms. PCSK9 Protein, Human (419a.a, HEK293, His) is the recombinant human-derived PCSK9 protein, expressed by HEK293, with C-His labeled tag.

HY-P705068

	PCSK9 Protein, Human (Biotinylated, D374Y, HEK293, His-Avi) Proprotein Convertase Subtilisin/Kexin Type 9; Neural Apoptosis-Regulated Convertase 1; NARC-1; Proprotein Convertase 9; PC9; Subtilisin/Kexin-Like Protease PC9; PCSK9; NARC1	Human	HEK293

HY-P70545

	PCSK9 Protein, Human (HEK293, V474I, G670E, His) Proprotein Convertase Subtilisin/Kexin Type 9; Neural Apoptosis-Regulated Convertase 1; NARC-1; Proprotein Convertase 9; PC9; Subtilisin/Kexin-Like Protease PC9; PCSK9; NARC1	Human	HEK293
	The PCSK9 protein is an important regulator of plasma cholesterol homeostasis, affecting LDL receptor family members such as LDLR and VLDLR. It promotes their intracellular degradation and enhances hepatic LDLR degradation through non-proteolytic mechanisms. PCSK9 Protein, Human (HEK293, V474I, G670E, His) is the recombinant human-derived PCSK9 protein, expressed by HEK293 , with C-6*His labeled tag and V474I, G670E mutation.

HY-P70546

	PCSK9 Protein, Human (Biotinylated, V474I, G670E, HEK293, His-HA-Avi) Proprotein Convertase Subtilisin/Kexin Type 9; Neural Apoptosis-Regulated Convertase 1; NARC-1; Proprotein Convertase 9; PC9; Subtilisin/Kexin-Like Protease PC9; PCSK9; NARC1	Human	HEK293
	The PCSK9 protein is an important regulator of plasma cholesterol homeostasis, affecting LDL receptor family members such as LDLR and VLDLR. It promotes their intracellular degradation and enhances hepatic LDLR degradation through non-proteolytic mechanisms. PCSK9 Protein, Human (Biotinylated, V474I, G670E, HEK293, His-HA-Avi) is the recombinant human-derived PCSK9 protein, expressed by HEK293 , with C-Avi, C-HA, C-8*His labeled tag and V474I, G670E mutation.

HY-P72405

	PCSK9 Protein, Human (Biotinylated, V474I, G670E, HEK293, Avi) Neural Apoptosis-Regulated Convertase 1; NARC-1; Proprotein Convertase 9; PC9	Human	HEK293
	The PCSK9 protein is an important regulator of plasma cholesterol homeostasis, affecting LDL receptor family members such as LDLR and VLDLR. It promotes their intracellular degradation and enhances hepatic LDLR degradation through non-proteolytic mechanisms. PCSK9 Protein, Human (Biotinylated, V474I, G670E, HEK293, Avi) is the recombinant human-derived PCSK9 protein, expressed by HEK293 , with C-Avi labeled tag and V474I, G670E mutation.

HY-P71189A

	PCSK9 Protein, Mouse (HEK293, His) 1 Publications Verification Proprotein Convertase Subtilisin/Kexin Type 9; Neural Apoptosis-Regulated Convertase 1; NARC-1; Proprotein Convertase 9; PC9; Subtilisin/Kexin-Like Protease PC9; PCSK9; Narc1	Mouse	HEK293
	The PCSK9 protein regulates cholesterol levels by degrading LDLR, VLDLR, LRP1/APOER, and LRP8/APOER2 receptors. It promotes LDLR degradation, inhibits recycling, induces ubiquitination, and affects APOB degradation. Additionally, PCSK9 influences BACE1 intermediates, ENaC surface expression, and neuronal apoptosis by modulating LRP8/APOER2 levels and anti-apoptotic signaling pathways. PCSK9 Protein, Mouse (HEK293, His) is the recombinant mouse-derived PCSK9 protein, expressed by HEK293, with C-6*His labeled tag.

HY-P70545A

	PCSK9 Protein, Human (HEK293, C-His) 1 Publications Verification Proprotein Convertase Subtilisin/Kexin Type 9; Neural Apoptosis-Regulated Convertase 1; NARC-1; Proprotein Convertase 9; PC9; Subtilisin/Kexin-Like Protease PC9; PCSK9; NARC1	Human	HEK293
	The PCSK9 protein is an important regulator of plasma cholesterol homeostasis, affecting LDL receptor family members such as LDLR and VLDLR. It promotes their intracellular degradation and enhances hepatic LDLR degradation through non-proteolytic mechanisms. PCSK9 Protein, Human (HEK293, C-His) is the recombinant human-derived PCSK9 protein, expressed by HEK293 , with C-6*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Host:	Mouse (1) Rabbit (2)
Reactivity:	Human (3)
Application:	IHC-P (1) IP (2) WB (2)
Isotype:	IgG (2)
Conjugation:	Non-conjugated (3) Biotin (5)
Clonality:	Monoclonal (2) Recombinant (1)
Modification:	Unmodified (2)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P81805

	PCSK9 Antibody (YA1550) HCHOLA3; LDLCQ1; NARC1; Neural apoptosis regulated convertase 1; PC9; PCSK9; Proprotein convertase 9	WB, IP	Human
	PCSK9 Antibody (YA1550) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PCSK9.

HY-P81805A

	PCSK9 Antibody (YA1550)(PBS only) HCHOLA3; LDLCQ1; NARC1; Neural apoptosis regulated convertase 1; PC9; PCSK9; Proprotein convertase 9	WB, IP	Human
	PCSK9 Antibody (YA1550) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PCSK9.

HY-P85725

	PCSK9 Antibody (YA5417) Proprotein convertase subtilisin/kexin type 9; Neural apoptosis-regulated convertase 1; NARC-1; Proprotein convertase 9; PC9; Subtilisin/kexin-like protease PC9;	IHC-P	Human
	PCSK9 Antibody (YA5417) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to PCSK9.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-132591

Inclisiran Maximum Cited Publications 7 Publications Verification ALN-PCSsc		siRNAs siRNA drugs
Inclisiran is a double-stranded small interfering RNA (siRNA) molecule. Inclisiran inhibits the transcription of *PCSK9. Inclisiran inhibits Pyroptosis, activates PPARγ, and reduces NLRP3, cleaved caspase-1, IL-1β, and IL-18*. Inclisiran has anti-inflammatory, lipid-regulating and anti-atherosclerotic activities. Inclisiran can be used in researches of hyperlipidemia and cardiovascular disease (CVD) .

HY-132591A

Inclisiran sodium Maximum Cited Publications 7 Publications Verification ALN-PCSsc sodium		siRNAs siRNA drugs
Inclisiran sodium is a double-stranded small interfering RNA (siRNA) molecule. Inclisiran sodium inhibits the transcription of *PCSK9. Inclisiran sodium inhibits Pyroptosis, activates PPARγ, and reduces NLRP3, cleaved caspase-1, IL-1β, and IL-18*. Inclisiran sodium has anti-inflammatory, lipid-regulating and anti-atherosclerotic activities. Inclisiran sodium can be used in researches of hyperlipidemia and cardiovascular disease (CVD) .

HY-150223

GalNAc unconjugated/naked Inclisiran 1 Publications Verification		siRNAs siRNA drugs
GalNAc unconjugated/naked Inclisiran is a double-stranded small interfering RNA molecule that targets hepatic *PCSK9* production to reduce LDL-C levels. GalNAc unconjugated/naked Inclisiran can be used in the research of cardiovascular diseases and hypercholesterolemia .

HY-143221

AS-Inclisiran sodium		siRNAs siRNA drugs
AS-Inclisiran sodium is the antisense of Inclisiran (HY-132591). Inclisiran is a double-stranded small interfering RNA (siRNA) molecule. Inclisiran inhibits the transcription of *PCSK9. Inclisiran inhibits Pyroptosis, activates PPARγ, and reduces NLRP3, cleaved caspase-1, IL-1β, and IL-18*. Inclisiran has anti-inflammatory, lipid-regulating and anti-atherosclerotic activities. Inclisiran can be used in researches of hyperlipidemia and cardiovascular disease (CVD) .

HY-148687A

SPC5001 sodium		Antisense Oligonucleotides
SPC5001 sodium is a locked nucleic acid (LNA)-modifed antisense oligonucleotide (ASO) complementary to human PCSK9 (proprotein convertase subtilisin/kexin type 9) mRNA. SPC5001 sodium can be used for the research of hypercholesterolemia. SPC5001 sodium sequence: 5′-TGmCTACAAAACmCmCA-3′ .

HY-143219

SS-Inclisiran sodium		siRNAs siRNA drugs
SS-Inclisiran sodium is a sense strand of Inclisiran (HY-132591) .

HY-158827A

AZD8233 sodium		Antisense Oligonucleotides
AZD8233 sodium, a liver-targeting antisense oligonucleotide (ASO), inhibits subtilisin/kexin type 9 (PCSK9) protein synthesis. AZD8233 sodium increases the available LDL receptors by reducing PCSK9 levels, thereby clearing LDL from the blood and decreasing LDL-C levels.

HY-143220

SS(no Galnac)-Inclisiran sodium		siRNAs siRNA drugs
SS (no Galnac)-Inclisiran sodium is the sense strand of Inclisiran (HY-132591) without GalNAc modification. Inclisiran is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of *PCSK-9*. SS (no Galnac)-Inclisiran sodium can be used in cardiovascular disease research .

HY-RS16505

Pcsk9 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Pcsk9 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pcsk9 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-147252A

Bezeparsen sodium		Antisense Oligonucleotides
Bezeparsen sodium is a PCSK9 synthesis inhibitor .

HY-148687

SPC5001		Antisense Oligonucleotides
SPC5001 is a locked nucleic acid (LNA)-modifed antisense oligonucleotide (ASO) complementary to human PCSK9 (proprotein convertase subtilisin/kexin type 9) mRNA. SPC5001 can be used for the research of hypercholesterolemia. SPC5001 sequence: 5′-TGmCTACAAAACmCmCA-3′ .

HY-RS22937

Pcsk9 Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Pcsk9 Rat Pre-designed siRNA Set A contains three designed siRNAs for Pcsk9 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10177

PCSK9 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
PCSK9 Human Pre-designed siRNA Set A contains three designed siRNAs for PCSK9 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-158827

AZD8233		Antisense Oligonucleotides
AZD8233, a liver-targeting antisense oligonucleotide (ASO), inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) protein synthesis. AZD8233 increases the available LDL receptors by reducing PCSK9 levels, thereby clearing LDL from the blood and decreasing LDL-C levels.

HY-158825

Cepadacursen sodium CIVI007 sodium		Antisense Oligonucleotides
Cepadacursen sodium is a liver-targeting antisense oligonucleotide (ASO), inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) protein synthesis. Cepadacursen sodium can be used for hypercholesterolemia research and the prevention of atherosclerotic cardiovascular disease (ASCVD).

HY-148689

SPC4061		Antisense Oligonucleotides
SPC4061 an antisense nucleotide, is a potent *PCSK9* inhibitor. SPC4061 targets the lock-in nucleic acid (LNA) of PCSK9 for the study of hypercholesterolemia and related diseases .

HY-148689A

SPC4061 sodium		Antisense Oligonucleotides
SPC4061 an antisense nucleotide, sodium is a potent *PCSK9* inhibitor. SPC4061 targets the lock-in nucleic acid (LNA) of PCSK9 for the study of hypercholesterolemia and related diseases .

HY-147252

Bezeparsen		Antisense Oligonucleotides
Bezeparsen is a PCSK9 synthesis inhibitor .

HY-171904

BCP-NC2-C12		Cationic Lipids
BCP-NC2-C12 is an ionizable cationic lipid. BCP-NC2-C12 can be used to generate lipid nanoparticles (LNPs) for in vivo delivery of mRNA. BCP-NC2-C12 LNPs mediated an approximately 90% reduction in PCSK9 serum protein levels via CRISPR/Cas9 gene knockout .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks